AVBP — ArriVent Biopharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapMomentum Trap

Annual balance sheet for ArriVent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—
Source:	PROSPECTUS	PROSPECTUS	10-K	10-K
Standards:	USG	USG	USG	USG
Status:	Final	Final	Final	Final
Cash
Short Term Investments
Cash and Short Term Investments	37.3	163	150	219
Net Total Receivables	0.25	0.5	0.761	0.5
Prepaid Expenses
Total Other Current Assets
Total Current Assets	43	183	160	227
Net Property, Plant And Equipment	0	0.139	0.291	0.154
Long Term Investments
Other Long Term Assets
Total Assets	43	183	163	275
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Current Liabilities	1.82	8.36	11.6	17.3
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	1.82	8.37	11.8	17.3
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	41.2	174	151	258
Total Liabilities & Shareholders' Equity	43	183	163	275
Total Common Shares Outstanding